Acumen Pharmaceuticals

Acumen Pharmaceuticals

Yahoo Finance • last month

VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform

By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany's Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides gr... Full story

Yahoo Finance • last month

Slate Medicines Appoints Mark W. Hahn to Board of Directors

By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25... Full story

Yahoo Finance • last month

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required... Full story

Yahoo Finance • 2 months ago

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the tre... Full story

Yahoo Finance • 2 months ago

Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer's Disease. The nomination comes after the company exercised its opt... Full story

Yahoo Finance • 2 months ago

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen’s option under its license agreement with JCR PharmaceuticalsEBD technology represents the only anti-amyloid oligomer program combining a validated blood... Full story

Yahoo Finance • 5 months ago

Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding

Earnings Call Insights: Acumen Pharmaceuticals (ABOS) Q4 2025 MANAGEMENT VIEW * Daniel O'Connell, CEO, highlighted 2025 as "a year of execution and expansion at Acumen." He reported demonstrable progress for the lead program, sabirnetu... Full story

Yahoo Finance • 5 months ago

Pre-Market Earnings Report for March 26, 2026 : CMC, DOO, SCVL, DBI, LOVE, LUCD, ABOS, CGTX, RMTI

The following companies are expected to report earnings prior to market open on 03/26/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Commercial Metals Company (CMC)is reporting for the quarter ending F... Full story

Yahoo Finance • 5 months ago

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidates in Acumen’s transferrin-receptor tar... Full story

Yahoo Finance • 6 months ago

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of... Full story

Yahoo Finance • 9 months ago

Healthcare Names Post Strong After-Hours Moves: KYMR, OCUL, POAI Among Top Gainers

(RTTNews) - Several healthcare and biotech names posted notable gains in Friday's after-hours trading session, with momentum driven by clinical updates, recent announcements, and technical rebounds. Kymera Therapeutics Inc. (KYMR) surged... Full story

Yahoo Finance • 9 months ago

Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching

The U.S. stock market has recently experienced a positive shift, with major indexes such as the Dow Jones and S&P 500 on track for their best week since June, following a brief trading halt due to technical issues. In this context of marke... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals stock maintains Buy rating at BTIG on promising Alzheimer's drug

Investing.com - BTIG has reiterated its Buy rating and $11.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), citing the company’s de-risked subcutaneous clinical candidate Sabirnetug for Alzheimer’s disease treatment. Accordin... Full story

Yahoo Finance • last year

Bullish Two Hundred Day Moving Average Cross - XHB

In trading on Monday, shares of the SPDR S&P Homebuilders ETF (Symbol: XHB) crossed above their 200 day moving average of $104.55, changing hands as high as $104.98 per share. SPDR S&P Homebuilders shares are currently trading up about 0.... Full story

Yahoo Finance • last year

Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz

[Close up of buildings in Wall Street] Alphotographic Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MON... Full story

Yahoo Finance • last year

Acumen, JCR Pharma Join To Develop Oligomer-targeted Enhanced Brain Delivery Therapy For Alzheimers

(RTTNews) - Acumen Pharmaceuticals (ABOS) announced a collaboration, option and license agreement with JCR Pharmaceuticals to develop an oligomer-targeted Enhanced Brain Delivery therapy for Alzheimers disease. JCR is a global specialty ph... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta ol... Full story

Yahoo Finance • last year

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the tre... Full story